Evidence map›Paper›PMID 32920979›Full record

ArticleMolecular oncology2021

Downregulation of miR-326 and its host gene β-arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth.

Evelina Miele, Agnese Po, Angela Mastronuzzi, Andrea Carai, Zein Mersini Besharat, Natalia Pediconi, Luana Abballe, Giuseppina Catanzaro, Claudia Sabato, Enrico De Smaele and 10 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Evelina MieleDepartment of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-4747-1032
Agnese PoDepartment of Molecular Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-9346-8782
Angela MastronuzziDepartment of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-4408-2373
Andrea CaraiNeurosurgery Unit, Department of Neurological and Psychiatric Sciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-5203-7855
Zein Mersini BesharatDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0003-0317-9854
Natalia PediconiCenter for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy.
Luana AbballeDepartment of Experimental Medicine, Sapienza University, Rome, Italy.
Giuseppina CatanzaroDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0001-8427-9691
Claudia SabatoDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0001-7533-4660
Enrico De SmaeleDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0003-4524-4423
Gianluca CanettieriDepartment of Molecular Medicine, Sapienza University, Rome, Italy.ORCID 0000-0001-6694-2613
Lucia Di MarcotullioDepartment of Molecular Medicine, Sapienza University, Rome, Italy.ORCID 0000-0003-0274-7178
Alessandra VaccaDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-0006-5379
Antonello MaiDepartment of Chemistry and Technologies of Drugs, Sapienza University of Rome, Italy.ORCID 0000-0001-9176-2382
Massimo LevreroCancer Research Center of Lyon (CRCL), UMR Inserm 1052 CNRS 5286 Mixte CLB, Université de Lyon 1 (UCBL1), France.ORCID 0000-0002-4978-0875
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany.ORCID 0000-0002-5447-5322
Marcel KoolDivision of Pediatric Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany.ORCID 0000-0002-6557-5468
Felice GiangasperoDepartment of Radiological, Oncological and Pathological Science, Sapienza University, Rome, Italy.ORCID 0000-0001-5382-2380
Franco LocatelliDepartment of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0002-7976-3654
Elisabetta FerrettiDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0001-7265-6429
Sapienza University of Rome · ITBambino Gesù Children's Hospital · ITGerman Cancer Research Center · DEIstituto Neurologico Mediterraneo · ITItalian Institute of Technology · ITUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent mortality rates of medulloblastoma (MB) and severe side effects of the current therapies require the definition of the molecular mechanisms that contribute to tumor progression. Using cultured MB cancer stem cells and xenograft tumors generated in mice, we show that low expression of miR-326 and its host gene β-arrestin1 (ARRB1) promotes tumor growth enhancing the E2F1 pro-survival function. Our models revealed that miR-326 and ARRB1 are controlled by a bivalent domain, since the H3K27me3 repressive mark is found at their regulatory region together with the activation-associated H3K4me3 mark. High levels of EZH2, a feature of MB, are responsible for the presence of H3K27me3. Ectopic expression of miR-326 and ARRB1 provides hints into how their low levels regulate E2F1 activity. MiR-326 targets E2F1 mRNA, thereby reducing its protein levels; ARRB1, triggering E2F1 acetylation, reverses its function into pro-apoptotic activity. Similar to miR-326 and ARRB1 overexpression, we also show that EZH2 inhibition restores miR-326/ARRB1 expression, limiting E2F1 pro-proliferative activity. Our results reveal a new regulatory molecular axis critical for MB progression.

Indexed as

Down-RegulationGene Expression Regulation, NeoplasticAnimalsbeta-Arrestin 1Cerebellar NeoplasmsE2F1 Transcription FactorFemaleHEK293 CellsHumansMaleMedulloblastomaMiceMice, Inbred NODMice, SCIDMicroRNAsNeoplasm ProteinsARRB1 protein, humanbeta-Arrestin 1E2F1 protein, humanE2F1 Transcription FactorMicroRNAsMIRN326 microRNA, humanNeoplasm ProteinsRNA, NeoplasmARRB1E2F1EZH2medulloblastomamiR-326

Identifiers

PMID32920979
PMCPMC7858128
OpenAlexW3085605041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.